38
total announcements
ALKEM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹59,830 Cr
P/E (TTM)
27.7
P/E (Forward)
22.4
EPS (TTM)
₹180.44
52W Low
₹4,975.50
52W High
₹5,933.50
Dividend Yield
0.40%
Beta
0.29
Price / Book
4.3
Debt / Equity
14.3
Revenue (TTM)
₹15,081 Cr
Gross Margin
64.80%
Operating Margin
17.80%
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as senior management personnel of the company, effective from October 12, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the appointment of Mr. Nilesh Vartak and Mr. Laxmikant Tiwari as senior management personnel of the company, effective from October 12, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the resignation of Chief Financial Officer, Mr. Nitin Agrawal, effective from 30th September, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the schedule of an Analyst / Institutional Investor meeting to be conducted on 7th October 2026 at HDFC Mutual Fund in Mumbai.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Alkem Laboratories Limited
Alkem Laboratories Limited has issued a corporate guarantee of Euro 54.45 Million to HSBC UK Bank plc for a term loan of Euro 49.5 Million availed by its step-down subsidiary Occlutech Holding AG in Switzerland.
Alkem Laboratories Limited
Alkem Laboratories Limited has launched NeuCeno (cenobamate), an anti-seizure medication for the treatment of partial-onset seizures in adult patients. The launch represents a significant advancement in the management of epilepsy in India.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company, effective from September 15, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has launched Renocia Exo, a patented Ginsenoside Exosome-based hair growth serum in India.
Alkem Laboratories Limited
Alkem Laboratories Limited held its 52nd Annual General Meeting on August 27, 2026, through video conferencing. The meeting was attended by 77 members, and all the directors were present. The company provided remote e-voting and e-voting facilities during the meeting. The resolutions related to the audited financial statements, payment of dividends, appointment of directors, and ratification of the cost auditor were passed with the requisite majority.
Alkem Laboratories Limited
Alkem Laboratories Limited has announced its Q1 FY2027 earnings, with revenue from operations at INR3,740 crores, a 11% year-on-year growth, and EBITDA margin at 20.5%, a 3.7% year-on-year growth. The company has outperformed the Indian pharmaceutical market in 7 key focus therapies, with growth rates ranging from 1.1x to 1.6x.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting) for the Scheme of Amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the publication of a newspaper advertisement regarding the disclosure of standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Alkem Laboratories Limited
Alkem Laboratories Limited has made available the audio recording of its Q1FY2027 Earnings Conference Call on its website.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure and opening dates pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Alkem Laboratories Limited
Alkem Laboratories has informed the Exchange about the approval of setting up a new block within its existing manufacturing facility at Baddi, Himachal Pradesh, and an investment of up to INR 75 crores.
Alkem Laboratories Limited
Alkem Laboratories Ltd. has announced its Q1FY27 financial results, with a 10.9% YoY growth in total revenue from operations. The company has outperformed the Indian Pharmaceutical Market (IPM) in several key therapies, and has received 05 ANDAs approvals in the US market. The company will hold a conference call on August 14, 2026, to discuss its financial results.
Alkem Laboratories Limited
Alkem Laboratories Limited has submitted the outcome of its Board Meeting held on 14th August, 2026, where the Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2026. The results and Limited Review Report of the Statutory Auditors are enclosed.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about an update on the US FDA inspection at its manufacturing facility located at Amaliya, Daman. The facility received a Form FDA 483 containing seven observations, and the US FDA has classified the inspection status as Official Action Indicated (OAI). The company continues to manufacture and supply approved products from the facility to the U.S. market.